bazedoxifene has been researched along with palbociclib in 2 studies
| Studies (bazedoxifene) | Trials (bazedoxifene) | Recent Studies (post-2010) (bazedoxifene) | Studies (palbociclib) | Trials (palbociclib) | Recent Studies (post-2010) (palbociclib) |
|---|---|---|---|---|---|
| 307 | 69 | 249 | 911 | 126 | 864 |
| Protein | Taxonomy | bazedoxifene (IC50) | palbociclib (IC50) |
|---|---|---|---|
| Chain B, Cell division protein kinase 6 | Homo sapiens (human) | 0.015 | |
| Chain B, Cell division protein kinase 6 | Homo sapiens (human) | 0.015 | |
| Cyclin-T1 | Homo sapiens (human) | 1.5085 | |
| Cyclin-K | Homo sapiens (human) | 1.207 | |
| Cyclin-dependent kinase 1 | Homo sapiens (human) | 9.8 | |
| Cyclin-dependent kinase 4 | Homo sapiens (human) | 0.0109 | |
| G2/mitotic-specific cyclin-B1 | Homo sapiens (human) | 9.8 | |
| Cyclin-A2 | Homo sapiens (human) | 2.2042 | |
| Acetylcholinesterase | Mus musculus (house mouse) | 0.021 | |
| G1/S-specific cyclin-D1 | Homo sapiens (human) | 0.0115 | |
| G1/S-specific cyclin-E1 | Homo sapiens (human) | 9.15 | |
| Cyclin-dependent kinase 2 | Homo sapiens (human) | 4.1887 | |
| G1/S-specific cyclin-D2 | Homo sapiens (human) | 0.0127 | |
| G1/S-specific cyclin-D3 | Homo sapiens (human) | 0.0194 | |
| Receptor-type tyrosine-protein kinase FLT3 | Homo sapiens (human) | 3.48 | |
| Cyclin-dependent kinase 9 | Homo sapiens (human) | 1.1821 | |
| Tyrosine-protein kinase JAK3 | Homo sapiens (human) | 0.0631 | |
| Cyclin-dependent kinase 6 | Homo sapiens (human) | 0.018 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brown, M; Buchwalter, G; Carlson, KE; Chandarlapaty, S; Dharmarajan, V; Fanning, SW; Fowler, CE; Greene, GL; Griffin, PR; Han, R; Hosfield, DJ; Houtman, R; Jeselsohn, R; Karimi, M; Katzenellenbogen, JA; Lainé, M; Martin, TA; Mayne, CG; Nettles, KW; Nowak, J; Nwachukwu, JC; Shen, Y; Tajkhorshid, E; Toy, W | 1 |
| Anderson, L; Cibulskis, C; Coorens, T; Getz, G; Grinshpun, A; Jeselsohn, R; Krop, IE; Lennon, NJ; Leshchiner, I; Li, T; McDonnell, DP; Nardone, A; Patterson, C; Rees, R; Russo, D; Stewart, C; Tayob, N; Tolaney, SM; Tsuji, J; Tung, N; Winer, EP | 1 |
1 trial(s) available for bazedoxifene and palbociclib
| Article | Year |
|---|---|
Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor-Positive Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Exome Sequencing; Female; Humans; Liquid Biopsy; Receptor, ErbB-2; Receptors, Estrogen; Treatment Outcome | 2022 |
1 other study(ies) available for bazedoxifene and palbociclib
| Article | Year |
|---|---|
The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells.
Topics: Breast Neoplasms; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Indoles; Ligands; MCF-7 Cells; Mutant Proteins; Mutation; Piperazines; Protein Binding; Protein Domains; Protein Structure, Secondary; Pyridines; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Structure-Activity Relationship; Tamoxifen | 2018 |